181 related articles for article (PubMed ID: 29198060)
1. No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA.
Vizeli P; Meyer Zu Schwabedissen HE; Liechti ME
Eur J Clin Pharmacol; 2018 Mar; 74(3):275-283. PubMed ID: 29198060
[TBL] [Abstract][Full Text] [Related]
2. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans.
Hysek CM; Simmler LD; Ineichen M; Grouzmann E; Hoener MC; Brenneisen R; Huwyler J; Liechti ME
Clin Pharmacol Ther; 2011 Aug; 90(2):246-55. PubMed ID: 21677639
[TBL] [Abstract][Full Text] [Related]
3. Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects.
Schmid Y; Rickli A; Schaffner A; Duthaler U; Grouzmann E; Hysek CM; Liechti ME
J Pharmacol Exp Ther; 2015 Apr; 353(1):102-11. PubMed ID: 25655950
[TBL] [Abstract][Full Text] [Related]
4. Role of Serotonin Transporter and Receptor Gene Variations in the Acute Effects of MDMA in Healthy Subjects.
Vizeli P; Meyer Zu Schwabedissen HE; Liechti ME
ACS Chem Neurosci; 2019 Jul; 10(7):3120-3131. PubMed ID: 30589533
[TBL] [Abstract][Full Text] [Related]
5. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
Cho SC; Kim BN; Cummins TD; Kim JW; Bellgrove MA
J Psychopharmacol; 2012 Mar; 26(3):380-9. PubMed ID: 21628343
[TBL] [Abstract][Full Text] [Related]
6. α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans.
Hysek CM; Fink AE; Simmler LD; Donzelli M; Grouzmann E; Liechti ME
J Clin Psychopharmacol; 2013 Oct; 33(5):658-66. PubMed ID: 23857311
[TBL] [Abstract][Full Text] [Related]
7. Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.
Hysek CM; Brugger R; Simmler LD; Bruggisser M; Donzelli M; Grouzmann E; Hoener MC; Liechti ME
J Pharmacol Exp Ther; 2012 Feb; 340(2):286-94. PubMed ID: 22034656
[TBL] [Abstract][Full Text] [Related]
8. Association between norepinephrine transporter gene (SLC6A2) polymorphisms and suicide in patients with major depressive disorder.
Kim YK; Hwang JA; Lee HJ; Yoon HK; Ko YH; Lee BH; Jung HY; Hahn SW; Na KS
J Affect Disord; 2014 Apr; 158():127-32. PubMed ID: 24655776
[TBL] [Abstract][Full Text] [Related]
9. Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects.
Vizeli P; Liechti ME
PLoS One; 2018; 13(6):e0199384. PubMed ID: 29912955
[TBL] [Abstract][Full Text] [Related]
10. Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial.
Liebe T; Li S; Lord A; Colic L; Krause AL; Batra A; Kretzschmar MA; Sweeney-Reed CM; Behnisch G; Schott BH; Walter M
Int J Neuropsychopharmacol; 2017 Nov; 20(11):909-918. PubMed ID: 29099972
[TBL] [Abstract][Full Text] [Related]
11. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).
Ramoz N; Boni C; Downing AM; Close SL; Peters SL; Prokop AM; Allen AJ; Hamon M; Purper-Ouakil D; Gorwood P
Neuropsychopharmacology; 2009 Aug; 34(9):2135-42. PubMed ID: 19387424
[TBL] [Abstract][Full Text] [Related]
12. Norepinephrine transporter gene variation modulates acute response to D-amphetamine.
Dlugos A; Freitag C; Hohoff C; McDonald J; Cook EH; Deckert J; de Wit H
Biol Psychiatry; 2007 Jun; 61(11):1296-305. PubMed ID: 17239355
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects.
Vizeli P; Schmid Y; Prestin K; Meyer Zu Schwabedissen HE; Liechti ME
Eur Neuropsychopharmacol; 2017 Mar; 27(3):232-238. PubMed ID: 28117133
[TBL] [Abstract][Full Text] [Related]
14. Further evidence of association between amphetamine response and SLC6A2 gene variants.
Dlugos AM; Hamidovic A; Palmer AA; de Wit H
Psychopharmacology (Berl); 2009 Oct; 206(3):501-11. PubMed ID: 19727679
[TBL] [Abstract][Full Text] [Related]
15. Oxytocin receptor gene variation predicts subjective responses to MDMA.
Bershad AK; Weafer JJ; Kirkpatrick MG; Wardle MC; Miller MA; de Wit H
Soc Neurosci; 2016 Dec; 11(6):592-9. PubMed ID: 26787430
[TBL] [Abstract][Full Text] [Related]
16. Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.
Hysek C; Schmid Y; Rickli A; Simmler LD; Donzelli M; Grouzmann E; Liechti ME
Br J Pharmacol; 2012 Aug; 166(8):2277-88. PubMed ID: 22404145
[TBL] [Abstract][Full Text] [Related]
17. Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy).
Hysek CM; Vollenweider FX; Liechti ME
Emerg Med J; 2010 Aug; 27(8):586-9. PubMed ID: 20378736
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT).
Pardo-Lozano R; Farré M; Yubero-Lahoz S; O'Mathúna B; Torrens M; Mustata C; Pérez-Mañá C; Langohr K; Cuyàs E; Carbó Ml; de la Torre R
PLoS One; 2012; 7(10):e47599. PubMed ID: 23112822
[TBL] [Abstract][Full Text] [Related]
19. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.
Freedman RR; Johanson CE; Tancer ME
Psychopharmacology (Berl); 2005 Dec; 183(2):248-56. PubMed ID: 16163516
[TBL] [Abstract][Full Text] [Related]
20. Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration.
Kolbrich EA; Goodwin RS; Gorelick DA; Hayes RJ; Stein EA; Huestis MA
J Clin Psychopharmacol; 2008 Aug; 28(4):432-40. PubMed ID: 18626271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
